Association of TGIFLX/Y mRNA expression with prostate cancer

• Published in: Medical oncology (Northwood, London, England) Vol. 26; no. 1; pp. 73 - 77
• Main Authors: Ousati Ashtiani, Z., Ayati, M., Modarresi, M. H., Raoofian, R., Sabah Goulian, B., Greene, W. K., Heidari, M.
• Format: Journal Article
• Language: English
• Published: New York Humana Press Inc 01.03.2009; Springer Nature B.V
• Subjects: Aged; Aged, 80 and over; Benign; Gene expression; Gene Expression Regulation, Neoplastic; Hematology; Homeobox; Homeodomain Proteins - biosynthesis; Homeodomain Proteins - genetics; Humans; Hyperplasia; Internal Medicine; Male; Medicine; Medicine & Public Health; Middle Aged; Molecular modelling; Oncology; Original Paper; Pathology; Polymerase chain reaction; Prostate cancer; Prostatic Hyperplasia - genetics; Prostatic Hyperplasia - metabolism; Prostatic Hyperplasia - pathology; Prostatic Neoplasms - genetics; Prostatic Neoplasms - metabolism; Prostatic Neoplasms - pathology; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger - biosynthesis; Solid tumors; Tumors; TGIFLX/Y; Homeobox gene; Prostate cancer; RT-PCR
• ISSN: 1357-0560; 1559-131X
• DOI: 10.1007/s12032-008-9086-7

Prostate cancer is the most common type of solid tumor and a leading cause of cancer-related death of men living in the developed world. In recent years, the molecular mechanisms involved in prostate cancer development and/or progression have been intensely studied and several genes have been identified. TGIFLX/Y ( TGIFLX and TGIFLY ) are members of the homeobox superfamily of genes whose function(s) is unknown. To investigate TGIFLX/Y mRNA expression in prostate cancer, we studied two different types of clinical samples, namely 60 prostate tumors and 15 cases of benign prostate hyperplasia (BPH), by RT-PCR. Our results revealed that most prostate tumors (73.5%) express at least one of these genes, although different patterns of TGIFLX/Y mRNA expression were observed. In some tumor samples the expression of both genes was detected, while in others no expression of either gene was observed. Notably, there was a significant correlation between expression of both TGIFLX and TGIFLY and a Gleason score of ≥6 ( P  = 0.038). By contrast, expression of TGIFLX/Y mRNA in BPH samples could not be detected. These results suggest an association of TGIFLX/Y expression with the progression of prostate cancer.